Charles River Laboratories International (CRL) had its price target raised by UBS Group AG from $170.00 to $175.00. They now have a "neutral" rating on the stock.
IQVIA Signs Agreement to Acquire Drug Discovery Assets from Charles River Laboratories, Expanding End-to-End Drug Discovery Capabilities [Yahoo! Finance]
Charles River Laboratories Provides Update on Planned Divestitures [Yahoo! Finance]
Charles River Laboratories Provides Update on Planned Divestitures
Baird Maintains Outperform Rating on Charles River Laboratories International, Inc. (CRL) [Yahoo! Finance]